Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug

Cationic lipid-conjugated dexamethasone as a selective antitumor agent

(2014) Samaresh Sau et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Glucocorticoid Receptor Knockdown Decreases the Antioxidant Protection of B16 Melanoma Cells: An Endocrine System-Related Mechanism that Compromises Metastatic Cell Resistance to Vascular Endothelium-Induced Tumor Cytotoxicity

(2014) Elena Obrador et al.   PLoS One

Drug Resistance in Cancer: An Overview

(2014) Genevieve Housman et al.   Cancers

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Glucocorticoid-independent Repression of Tumor Necrosis Factor (TNF) α-stimulated Interleukin (IL)-6 Expression by the Glucocorticoid Receptor

(2011) Nicolette J. D. Verhoog et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer

(2011) Joyce O'Shaughnessy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

A Novel Inhibitor of Signal Transducers And Activators Of Transcription 3 Activation Is Efficacious Against Established Central Nervous System Melanoma and Inhibits Regulatory T Cells

(2008) L.-Y. Kong et al.   CLINICAL CANCER RESEARCH